ImmunoACT

ImmunoACT is an IIT Bombay incubated company, which is a pioneer in the field of cell & gene therapy. It has developed India’s first and fully indigenously developed CAR-T therapy for the treatment of refractory/relapsing B-cell malignancies (NexCAR19) and has an an aggressive pipeline to treat liquid and solid tumors. With a strong R&D and strategic collaborations ImmunoACT is paving the way towards affordable and accessible gene-modified cell therapies specially with an emphasis on resource-constrained economies.

Our first state-of-the-art cGMP facility has been operational since mid-2022, and we are scaling our R&D, manufacturing and commercial capabilities in India and beyond to serve the clinically unmet needs of patients through advanced therapeutics.

 Our Vision:

To be a Leader in Cell & Gene Therapy for the Long-Term Cure of Patients, through Translational Research in India & beyond

 Our Values:

·        Accessible and Affordable to all

·        Cutting-edge Research

·        Transforming ideas to Reality

Become a part of this revolution in the healthcare industry - grow your career with us.

Website – https://www.immunoact.com/ - Visit our website, understand about us.

LinkedIn Profile - https://www.linkedin.com/company/immunoact/